A molecule solves psoriasis?: Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses

被引:63
作者
Ghoreschi, K
Mrowietz, U
Röcken, M
机构
[1] Univ Tubingen, Dept Dermatol, D-72076 Tubingen, Germany
[2] Univ Schleswig Holstein, Dept Dermatol, Kiel, Germany
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2003年 / 81卷 / 08期
关键词
psoriasis; autoimmune disease; T helper cell 1; T helper cell 2; interleukin; 4;
D O I
10.1007/s00109-003-0460-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Psoriasis is an autoimmune disease affecting 2-4% of the Caucasian population. Inflammatory processes induce the migration of interferon (IFN) gamma producing Th1 lymphocytes into the skin. These play a key role in the pathogenesis of psoriasis. These Th1 lymphocytes are responsible for the pathological reactions in psoriatic skin leading to keratinocyte hyperproliferation, small vessel proliferation and neutrophilic infiltration. Antigen-presenting cells activate dermal CD4(+) T lymphocytes, and various signals can support the polarization of Th1 responses. The main signal for Th1 development is interleukin (IL) 12. After binding to their receptors both IL-12 and IFN-gamma promote intracellular IFN-gamma production by activating signal transducer and activator of transcription (STAT) 4 or 1. STAT1 activation by IFN-gamma is followed by T-bet activation, a master transcription factor for Th1 lymphocytes. In experimental models of Th1-mediated autoimmune diseases immune deviation of polarized autoreactive Th1 into anti-inflammatory Th2 responses generally improves the disease. Therefore new therapeutic approaches based on immunomodulating molecules have been developed for psoriasis, a prototypical Th1-mediated autoimmune disorder. Recently IL-4, the most effective Th2-inducing cytokine, has been shown to be safe and efficient for treating psoriasis. Improvement was associated with the induction of a Th2 phenotype of skin infiltrating lymphocytes. This review summarizes the IL-4 inducing potential of various conventional and newer systemic therapies for psoriasis. Many of these were thought to be primarily immunosuppressive. A review of the literature reveals that most of them can induce IL-4 and Th2, and that Th2 induction may be an underestimated mode of action in the therapy of Th1-mediated autoimmune disease. Further studies are needed to determine the central role of IL-4 in the control of Th1-induced autoimmune disease, namely psoriasis.
引用
收藏
页码:471 / 480
页数:10
相关论文
共 102 条
  • [71] Psoriasis vulgaris - a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis
    Prinz, JC
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (04) : 326 - 332
  • [72] RACKE MK, 1995, J IMMUNOL, V154, P450
  • [73] CYTOKINE-INDUCED IMMUNE DEVIATION AS A THERAPY FOR INFLAMMATORY AUTOIMMUNE-DISEASE
    RACKE, MK
    BONOMO, A
    SCOTT, DE
    CANNELLA, B
    LEVINE, A
    RAINE, CS
    SHEVACH, EM
    ROCKEN, M
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (05) : 1961 - 1966
  • [74] Transcription factors of the NFAT family: Regulation and function
    Rao, A
    Luo, C
    Hogan, PG
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 : 707 - 747
  • [75] Promoter polymorphisms of the genes encoding tumor necrosis factor-α and interleukin-1β are associated with different subtypes of psoriasis characterized by early and late disease onset
    Reich, K
    Mössner, R
    König, IR
    Westphal, G
    Ziegler, A
    Neumann, C
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 118 (01) : 155 - 163
  • [76] Treatment of psoriasis with interleukin-10
    Reich, K
    Brück, M
    Gräfe, A
    Vente, C
    Neumann, C
    Garbe, C
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 111 (06) : 1235 - 1236
  • [77] Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology
    Reynolds, NJ
    Al-Daraji, WI
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2002, 27 (07) : 555 - 561
  • [78] IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease
    Rocken, M
    Racke, M
    Shevach, EM
    [J]. IMMUNOLOGY TODAY, 1996, 17 (05): : 225 - 231
  • [79] INFECTION BREAKS T-CELL TOLERANCE
    ROCKEN, M
    URBAN, JF
    SHEVACH, EM
    [J]. NATURE, 1992, 359 (6390) : 79 - 82
  • [80] ANTIGEN-SPECIFIC ACTIVATION, TOLERIZATION, AND REACTIVATION OF THE INTERLEUKIN-4 PATHWAY IN-VIVO
    ROCKEN, M
    URBAN, J
    SHEVACH, EM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (06) : 1885 - 1893